|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Investments, at fair value (amortized cost $588,389 and $607,574, respectively) | |||||||||||||||||
| Non-controlled/non-affiliate company investments | |||||||||||||||||
| Non-controlled affiliate company investments | |||||||||||||||||
| Controlled affiliate company investments | |||||||||||||||||
| Total investments, at fair value (amortized cost $588,389 and $607,574, respectively) | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Restricted cash and cash equivalents | |||||||||||||||||
| Restricted foreign currency (cost of $52 and $405, respectively) | |||||||||||||||||
| Interest and dividend receivable | |||||||||||||||||
| Amounts receivable on unsettled investment transactions | |||||||||||||||||
| Escrow receivable | |||||||||||||||||
| Prepaid expenses and other receivables | |||||||||||||||||
| Unrealized appreciation on foreign currency forward contracts | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities | |||||||||||||||||
| Debt (net of unamortized debt issuance costs of $3,744 and $4,666, respectively) | |||||||||||||||||
| Distributions payable | |||||||||||||||||
| Management fees payable | |||||||||||||||||
| Incentive fees payable | |||||||||||||||||
| Amounts payable on unsettled investment transactions | |||||||||||||||||
| Interest payable | |||||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||||
| Advances received from unfunded credit facilities | |||||||||||||||||
| Unrealized depreciation on foreign currency forward contracts | |||||||||||||||||
| Amounts payable for common stock repurchased | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Net assets | |||||||||||||||||
| Common stock, 21,476,471 and 22,234,045 shares issued and outstanding, par value $0.001 per share, respectively, and 100,000,000 shares authorized | |||||||||||||||||
| Paid-in capital in excess of par | |||||||||||||||||
| Accumulated earnings (losses) | |||||||||||||||||
| Total net assets | |||||||||||||||||
| Total liabilities and total net assets | |||||||||||||||||
| Number of shares outstanding | |||||||||||||||||
| Net asset value per share |
Loading...